middle.news
Lumos and BARDA Launch $6.2M Pediatric Study to Expand FebriDx Use in US
9:30am on Monday 1st of September, 2025 AEST
•
Healthcare
Read Story
Lumos and BARDA Launch $6.2M Pediatric Study to Expand FebriDx Use in US
9:30am on Monday 1st of September, 2025 AEST
Key Points
BARDA funds $6.2 million pediatric FebriDx clinical study
Study targets children aged 2–12 in CLIA-waived U.S. settings
FebriDx currently FDA-cleared for ages 12–64 in urgent care
Expansion could increase addressable U.S. market 15-fold
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Lumos Diagnostics Holdings (ASX:LDX)
OPEN ARTICLE